Industry Outlook

Opentrons partners with Zymo Research to automate key microbiome chemistries on the Opentrons Flex™

Opentrons partners with Zymo

Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics and Zymo Research Corp, a life science reagent company, are collaborating to transform microbiome and metagenome analysis by fully automating comprehensive, end-to-end workflows from sample collection through library preparation on the Opentrons Flex.

Traditional methods of microbiome analysis have provided valuable insights across various applications; however, this approach frequently faces challenges in terms of time, cost, and accuracy. Additionally, these methods often demand significant labor from skilled personnel, which may hinder scalability and reproducibility. The innovative collaboration between Zymo and Opentrons, which combines the automation capabilities of the Opentrons Flex platform with Zymo chemistries, offers numerous advantages over conventional approaches, including enhanced throughput, minimized variability, and superior data quality.

The Opentrons Flex platform enables the ability to perform multiple chemistries simultaneously, significantly reducing the risk of sample loss, contamination, or variability. Furthermore, the platform executes these chemistries with remarkable precision and reproducibility, thereby increasing the accuracy and sensitivity of data. Lastly, the Opentrons Flex streamlines the research process by automating monotonous and time-consuming tasks, enabling researchers to dedicate their efforts to the analysis and interpretation of data. This revolutionary collaboration has the potential to redefine the landscape of microbiome analysis, setting new standards in efficiency and accuracy.

James Atwood, General Manager of Opentrons Robotics said, "We're delighted to bring accessible automation for the ZymoBIOMICS range of chemistries to the Opentrons Flex platform in support of our vibrant robotics community. Automated microbiome sample prep workflows are of growing interest to our members involved in pathogen surveillance and microbiome-based therapeutic development. Our partnership with Zymo extends our commitment to providing our users with highly qualified protocols, available on demand, through our protocol library."

"Microbiome research plays a crucial role in advancing human health, agriculture, and environmental sustainability, necessitating the integration of interdisciplinary and collaborative strategies," said Dr. Marc Van Eden, VP of Business Development at Zymo Research. "By streamlining and standardizing microbiome analysis through the combined use of the Opentrons Flex platform and Zymo's chemistries, this partnership can accelerate the progress and influence of microbiome research. Consequently, this innovative approach holds the potential to unlock groundbreaking discoveries and applications in various fields as we master the microbiome."

Zymo and Opentrons have a successful history of collaboration, having automated popular Zymo chemistries, including ZymoBIOMICS, Quick-DNA, and Direct-Zol™ chemistries on Opentrons' reliable and affordable personal pipetting robot, the OT-2. These protocols have been written and verified by the Zymo automation team and are available in Opentrons' open repository of protocols, the Protocol Library. In addition, over 20 protocols are automating Zymo kits contributed by our community.

About Opentrons Flex

The Opentrons Flex features easily reconfigurable, modular hardware including swappable pipettes ranging from 1 to 96 channels, plate gripper, on-deck thermocycler, heater-shaker, magnetic plate, and more. The Opentrons software ecosystem includes a robust library of more than 500 protocols, plus easy drag-and-drop cloud software to enable you to create protocols for your specific needs. The Flex's modern API allows for near-limitless control over the robot and enables seamless integrations to build scalable workflows.

The Opentrons Flex NGS Workstation can automate many popular NGS library prep kits, including tagmentation- and fragmentation-based chemistries, with pricing starting below $50,000; the Opentrons Flex Protein Purification Workstation can automate magnetic bead-based protein purification workflows, with pricing starting below $40,000; the Opentrons Flex Aliquoting Workstation starts below $20,000.

The ZymoBIOMICS DNA Kits are microbial DNA purification kits designed for purifying DNA from a variety of sample inputs that are immediately ready for microbiome or metagenome analyses. These microbial DNA purification kits include the ZymoBIOMICS lysis system which eliminates bias associated with unequal lysis efficiencies of different organisms (e.g. Gram-negative/positive bacteria, fungus, protozoans, and algae), making it ideal for microbial community profiling. Uniform mechanical lysis of all microbes is achieved by bead beating with the innovative ultra-high density BashingBeads. These microbial DNA purification kits are equipped with our OneStep PCR Inhibitor removal technology, enabling PCR amplification from DNA derived from inhibitor-rich environmental samples. Purified DNA from these microbial DNA purification kits is ideal for all downstream applications including PCR, arrays, 16S rRNA gene sequencing, and shotgun sequencing.

About ZymoBIOMICS

The ZymoBIOMICS DNA Kits are microbial DNA purification kits designed for purifying DNA from a variety of sample inputs that are immediately ready for microbiome or metagenome analyses. These microbial DNA purification kits include the ZymoBIOMICS lysis system which eliminates bias associated with unequal lysis efficiencies of different organisms (e.g. Gram-negative/positive bacteria, fungus, protozoans, and algae), making it ideal for microbial community profiling. Uniform mechanical lysis of all microbes is achieved by bead beating with the innovative ultra-high density BashingBeads. These microbial DNA purification kits are equipped with our OneStep PCR Inhibitor removal technology, enabling PCR amplification from DNA derived from inhibitor-rich environmental samples. Purified DNA from these microbial DNA purification kits is ideal for all downstream applications including PCR, arrays, 16S rRNA gene sequencing, and shotgun sequencing.

About Opentrons

Opentrons Labworks, Inc., a disruptive life science company and the current market leader in entry-level lab automation, accelerates innovation in research and healthcare through its integrated lab platform, which includes business units Opentrons Robotics and Neochromosome. Opentrons has raised over $200 million in funding and achieved unicorn status based on the first- and second-generation robots, OT-One and OT-2. Opentrons Robotics provides thousands of institutions with flexible, easy-to-use lab robots, automating R&D operations and making robotics, a vast open-source library accessible to life sciences researchers worldwide. Neochromosome offers world-class genome-scale cell engineering solutions for biopharma and biotech. Trusted by institutions such as Mayo Clinic, Stanford, Harvard, and MIT, Opentrons is found in thousands of academic, biopharma, synthetic biology and clinical research labs in more than 40 countries.

About Zymo Research

Zymo Research is a privately owned company that has been serving the scientific community with state-of-the-art molecular biology tools since 1994. "The Beauty of Science is to Make Things Simple" is their motto, which is reflected in every product they produce, from their epigenetics to DNA/RNA purification technologies. Historically recognized as the leader in epigenetics, Zymo Research is breaking boundaries with novel solutions for sample collection, microbiomic measurements, and NGS technologies that are high quality and simple to use.

Spotlight

Other News
Medical

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

Personalis, Inc. | February 05, 2024

Personalis, Inc. a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform. “We have built a unique pharma channel based on our industry-leading tissue and MRD assays and ClearNote Health’s blood-based epigenomic approach is complementary to our offering as it helps our customers deepen their understanding of a patient’s response to immunotherapies,” said Chris Hall, CEO and President of Personalis. “Commercial partnerships such as this broaden our portfolio and are expected to appeal to a wide range of biopharma customers and accelerate our revenue growth.” Echoing this sentiment, Dave Mullarkey, CEO of ClearNote Health, remarked, “Partnering with Personalis presents an excellent opportunity to bring our 5hmC technology to the forefront of cancer research. This alliance is a testament to the synergy between our two companies, enabling us to expand our reach and significantly impact the biopharmaceutical industry. Together, we can accelerate the development of personalized therapies and make a real difference in the lives of patients.” ClearNote Health’s Epigenomics Platform represents a groundbreaking advance in cancer detection, offering real-time insights into disease-specific pathways. By tracking changes in 5hmC levels coupled with artificial intelligence-based analytical methods, the platform can detect cancer earlier, monitor disease progression, understand mechanisms of resistance, and identify promising drug targets and biomarkers. These insights are invaluable for optimizing drug development programs and delivering more effective treatments to patients. The Epigenomics Platform identifies changes in gene activation and gene regulation by labeling specific changes in the 5hmC landscape from plasma-derived cell-free DNA. This rich biological information, as part of clinical trials, enables the monitoring of cancer therapies in real time and contributes to an understanding of drug resistance mechanisms. The partnership marks a pivotal moment in cancer research, leveraging the strengths of both companies to offer unparalleled solutions in the biopharmaceutical industry. About ClearNote Heath, Inc. ClearNote Health is a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives. Utilizing a standard blood draw, the company applies its proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases, ClearNote Health identifies cancers before they progress and when patients are most likely to benefit from treatment. ClearNote Health’s first commercially available test is the Avantect™ Pancreatic Cancer Test, which detects the presence of pancreatic cancer signals in patients at high risk of the disease, including those recently diagnosed with Type 2 diabetes. ClearNote Health is headquartered in San Diego, with additional presence in the San Francisco Bay area and internationally. The company’s CLIA- and CAP-accredited laboratory is located in San Diego, Calif. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California.

Read More